Email this article 
OMALIZUMAB: INNOVATIVE APPROACH TO THERAPY OF DIFFICULT TO CONTROL SEVERE ASTHMA AND COMORBID DISEASES In cHILDREN
- Authors: Tsyplenkova SE1, Mizernitslcy YL1, Sokolova LV1, Sorokina EV1
-
Affiliations:
- Research and Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical University
- Issue: Vol 11, No 5 (2014)
- Pages: 57-60
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/537
- DOI: https://doi.org/10.36691/RJA537
- ID: 537
Cite item
Open Access
Access granted
Abstract
The paper summarizes the 5-year experience of omalizumab (Xolair) use in severe atopic uncontrolled asthma and related allergic diseases treatment in children; proposed basic criteria for selection of patients for this treatment.
Full Text
About the authors
S E Tsyplenkova
Research and Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical University
Email: stsiplenkova@rambler.ru
Moscow
Y L Mizernitslcy
Research and Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical UniversityMoscow
L V Sokolova
Research and Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical UniversityMoscow
E V Sorokina
Research and Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical UniversityMoscow
References
- Bames P.J. AntiIgE-therapy in asthma: rationale and therapeutic potential. Int. Arch. Allergy Immunol. 2000, v. 123, р. 196-204.
- Фассахов Р.С. Ксолар (омализумаб): новые возможности терапии тяжелой бронхиальной астмы. пульмонология. 2007, № 4, с. 100-105.
- Holgate S.T, Chuchalin A.G., Herbert J. et al. Efficacy and safety a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy. 2004, v. 34, р. 632-638.
- Княжеская Н.п. перспективы использования антиIgE- препаратов в терапии аллергических заболеваний. пульмонология детского возраста: проблемы и решения. 2004, № 4, с. 191-192.
- Мизерницкий Ю.Л., Цыпленкова С.Э. Ксолар - новые возможности в терапии тяжелой бронхиальной астмы у детей. Атмосфера. Пульмонология и аллергология. 2008, № 3, с. 33-36.
- Куличенко Т.В. Омализумаб в лечении аллергических болезней. Педиатр. фармакол. 2007, № 4, с. 63-71.
- Bousquet J., Rabe K., Humbert M. et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir. Med. 2007, v. 101, р. 1482-1483.
- Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика» (4-е изд., испр. и перераб.). М., «Оригинал-макет». 2012, 184 с.
- Soresi S., Togias A. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc. 2006, v. 27, р. 15-23.
- Chapman K.R., Cartier A., Mclvor R.A. et al. The role of omalizumab in the treatment of severe allergic asthma. Can. Respir. J. 2006, v. 13, р. 1-9.
- De Buske L.M. IgE, allergic diseases, and omalizumab. Curr. Pharm. Des. 2006, v. 12, р. 3929-3944.
- Johansson S.G., Oman H., Nopp A. et al. The importance of IgE antibody levels in anti-IgE treatment. Allergy. 2006, v. 61, р. 1216-1219.
- Walker S., Monteil M., Phelan K. et al. Anti-IgE for chronic asthma in adult and children. Cochrane Database Syst. Rev. 2003, v. 3, CD003559.
- Silkoff P.E., Romero F.A., Gupta N. et al. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics. 2004, v. 113, р. 308-312.
- Diarmuid M., McNicholl, Michael Stevenson et al. The utility of fractional exhaled nitric oxide suppression in the identification of non-adherence in difficult asthma. Am. J. Respir. Crit. Care Med. 2012, v. 186, р. 1102-1108.
- Климко Н.Н., Андреев Б.В., Колбин А.С. Фармакоэкономический аспект применения омализумаба у пациентов с бронхиальной астмой. Педиатр. фармакол. 2008, № 4, с. 38-44.
Supplementary files
